LODALIS 3.75 G
COLESEVELAM HYDROCHLORIDE : 3.75 G · DIN 02432463 · BAUSCH HEALTH, CANADA INC.
Health Canada status: DORMANT
What is LODALIS?
LODALIS 3.75 G contains COLESEVELAM HYDROCHLORIDE : 3.75 G. It is listed in the Health Canada Drug Product Database under DIN 02432463, held by BAUSCH HEALTH, CANADA INC., supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LODALIS used for?
Adjunct to diet for reduction of cholesterol in patients with hypercholesterolemia (Type IIa) who are not controlled with a statin alone or are unable to tolerate a statin.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02432463 |
|---|---|
| Brand name | LODALIS |
| Generic / active ingredient | COLESEVELAM HYDROCHLORIDE : 3.75 G |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 3.75 G |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AC04 COLESEVELAM |
| AHFS class | 24:06.04 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 31-Jul-2026 |
| Original market date | 2015-04-02 00:00:00 |
How is it administered?
Tablets: 3.75g to 4.375g daily (6-7 tablets) once or twice daily with meals. Suspension: One 3.75g packet once daily with a meal. Take with liquid.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section header present but details missing in snippet).
How is it supplied?
Not explicitly detailed in provided text (mentions packets for suspension and tablets).
Contraindications
Hypersensitivity to the drug or any ingredient; bowel or biliary obstruction.
Warnings and precautions
Can induce/worsen constipation; caution in patients with CHD/angina. Monitor TG levels. Monitor INR in warfarin patients. Monitor glucose/HbA1c in diabetics.
What can be used instead?
Other Canadian products sharing ATC code C10AC04 COLESEVELAM. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-COLESEVELAM | 625 MG | TABLET | APOTEX INC | MARKETED | DIN 02494051 |
| LODALIS | 625 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02373955 |
Who else supplies COLESEVELAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COLESEVELAM appears in 2 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.